CN111032658B - 作为C5a抑制剂的5-5稠合环类 - Google Patents

作为C5a抑制剂的5-5稠合环类 Download PDF

Info

Publication number
CN111032658B
CN111032658B CN201880036650.8A CN201880036650A CN111032658B CN 111032658 B CN111032658 B CN 111032658B CN 201880036650 A CN201880036650 A CN 201880036650A CN 111032658 B CN111032658 B CN 111032658B
Authority
CN
China
Prior art keywords
compound
group
pharmaceutically acceptable
acceptable salt
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880036650.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN111032658A (zh
Inventor
樊平臣
C·W·兰格
R·M·路易
V·马拉索恩
V·R·马利
S·普那
曾一斌
张朋烈
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chemocentryx Inc
Original Assignee
Chemocentryx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemocentryx Inc filed Critical Chemocentryx Inc
Publication of CN111032658A publication Critical patent/CN111032658A/zh
Application granted granted Critical
Publication of CN111032658B publication Critical patent/CN111032658B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Liquid Crystal Substances (AREA)
  • Glass Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Insulating Materials (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201880036650.8A 2017-05-31 2018-05-29 作为C5a抑制剂的5-5稠合环类 Active CN111032658B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762513025P 2017-05-31 2017-05-31
US62/513,025 2017-05-31
PCT/US2018/034908 WO2018222601A1 (en) 2017-05-31 2018-05-29 5-5 FUSED RINGS AS C5a INHIBITORS

Publications (2)

Publication Number Publication Date
CN111032658A CN111032658A (zh) 2020-04-17
CN111032658B true CN111032658B (zh) 2022-12-20

Family

ID=64455572

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880036650.8A Active CN111032658B (zh) 2017-05-31 2018-05-29 作为C5a抑制剂的5-5稠合环类

Country Status (16)

Country Link
US (2) US10683294B2 (https=)
EP (1) EP3630774B1 (https=)
JP (1) JP7141129B2 (https=)
KR (1) KR102586710B1 (https=)
CN (1) CN111032658B (https=)
AR (1) AR111841A1 (https=)
AU (1) AU2018277523B2 (https=)
CA (1) CA3064025A1 (https=)
ES (1) ES2934507T3 (https=)
IL (1) IL270842B2 (https=)
MA (1) MA48800A (https=)
MX (1) MX391392B (https=)
NZ (1) NZ759295A (https=)
TW (1) TWI813570B (https=)
WO (1) WO2018222601A1 (https=)
ZA (1) ZA201907755B (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110997674B (zh) 2017-05-31 2022-12-20 凯莫森特里克斯股份有限公司 作为C5a抑制剂的6-5稠合环类
WO2018222601A1 (en) 2017-05-31 2018-12-06 Chemocentryx, Inc. 5-5 FUSED RINGS AS C5a INHIBITORS
MX2020006460A (es) 2017-12-22 2020-11-06 Chemocentryx Inc Compuestos de anillo 5,5 fusionado sustituido con diarilo como inhibidores de c5ar.
ES2980175T3 (es) 2017-12-22 2024-09-30 Chemocentryx Inc Compuestos anulares fusionados en 6,5 sustituidos con diarilo como inhibidores de C5aR
WO2019195159A1 (en) * 2018-04-02 2019-10-10 Chemocentryx, Inc. PRODRUGS OF FUSED-BICYCLIC C5aR ANTAGONISTS
BR112021025888A2 (pt) 2019-07-10 2022-04-26 Chemocentryx Inc Indanos como inibidores de pd-l1
CN112300169B (zh) * 2019-07-26 2022-03-04 上海美迪西生物医药股份有限公司 吡咯并吡唑类衍生物、其制备方法及其在医药上的应用
CN114555080B (zh) 2019-10-16 2025-10-10 凯莫森特里克斯股份有限公司 用于治疗pd-l1疾病的杂芳基联苯胺
AU2020368393B2 (en) 2019-10-16 2026-01-08 Chemocentryx, Inc. Heteroaryl-biphenyl amides for the treatment of PD-L1 diseases
EP4219453A4 (en) * 2020-09-28 2024-10-09 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. PYRAZOLE COMPOUND AND ITS PREPARATION METHOD AND ITS USE
WO2022093971A1 (en) 2020-10-28 2022-05-05 Chemocentryx, Inc. Methods of treating hidradenitis suppurativa

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006042102A2 (en) * 2004-10-05 2006-04-20 Neurogen Corporation Pyrrolo-pyridine, pyrrolo-pyrimidine and related heterocyclic compounds
CN1777605A (zh) * 2003-04-23 2006-05-24 辉瑞产品公司 大麻素受体配位体及其用途
CN104936960A (zh) * 2012-08-16 2015-09-23 詹森药业有限公司 作为n型钙通道阻滞剂的吡咯并吡唑

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2349762T3 (es) 2000-08-10 2011-01-11 Pfizer Italia S.R.L. Biciclo-pirazoles activos como inhibidores de quinasas, procedimientos para su preparación y composiciones farmacéuticas que los comprenden.
EP1322309B1 (en) 2000-09-29 2008-08-13 Neurogen Corporation High affinity small molecule c5a receptor modulators
SE524438C2 (sv) 2000-10-05 2004-08-10 Magnus Georg Goertz Fjärrstyrt dörrelaterat låsarrangemang, första och andra datorpogramprodukt, bärande medium och ett datorlösbart medium
US7902179B2 (en) 2001-04-26 2011-03-08 Ajinomoto Co., Inc. Heterocyclic compounds
ITMI20012025A1 (it) 2001-09-28 2003-03-28 Dompe Spa Sali di ammonio quaternari di omega-amminoalchilammidi di acidi r 2-aril-propionici e composizioni farmaceutiche che li contengono
EP1487796A4 (en) 2002-03-28 2005-11-16 Neurogen Corp SUBSTITUTED BIARYLAMIDES AS MODULATORS OF THE C5A RECEPTOR
AU2003218374A1 (en) 2002-03-28 2003-10-13 Neurogen Corporation Substituted tetrahydroisoquinolines as c5a receptor modulators
WO2003084524A1 (en) 2002-03-29 2003-10-16 Neurogen Corporation Combination therapy for the treatment of conditions with pathogenic inflammatory components
EP1534680B1 (en) 2002-08-14 2012-02-22 Pharmaco Investments, Inc. Prenylation inhibitors and methods of their synthesis and use
WO2004018460A1 (en) 2002-08-21 2004-03-04 Neurogen Corporation Amino methyl imidazoles as c5a receptor modulators
ATE552253T1 (de) 2002-11-08 2012-04-15 Novartis Int Pharm Ltd 3-substituierte-6-aryl- pyridin derivate als liganden für c5a-rezeptoren
US20040214856A1 (en) 2003-04-23 2004-10-28 Pfizer Inc Cannabinoid receptor ligands and uses thereof
AU2003902354A0 (en) 2003-05-15 2003-05-29 Harkin, Denis W. Treatment of haemorrhagic shock
WO2005007087A2 (en) 2003-07-03 2005-01-27 Neurogen Corporation Substituted (heterocycloalkyl)methyl azole derivatives as c5a receptor modulators
US7598255B2 (en) 2005-08-04 2009-10-06 Janssen Pharmaceutica Nv Pyrimidine compounds as serotonin receptor modulators
US20070112015A1 (en) 2005-10-28 2007-05-17 Chemocentryx, Inc. Substituted dihydropyridines and methods of use
BRPI0909945A2 (pt) 2008-06-20 2015-07-28 Genentech Inc "composto, composição farmacêutica, método para tratar ou atenuar a gravidade de uma doença ou condição responsiva à inibição da atividade jak2 quinase em um paciente, kit para o tratamento de uma doença ou distúrbio responsivo à inibição da jak quinase"
CA2965223C (en) 2008-12-22 2019-09-24 Chemocentryx, Inc. C5ar antagonists
US20110275639A1 (en) 2008-12-22 2011-11-10 Chemocentryx, Inc. C5aR ANTAGONISTS
PT2585064T (pt) 2010-06-24 2017-08-08 Chemocentryx Inc Antagonistas do c5ar
US8846656B2 (en) 2011-07-22 2014-09-30 Novartis Ag Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as C5a receptor modulators
CN103421006B (zh) 2013-08-18 2016-06-22 上海师范大学 2,3,5,7-四取代二氢吡唑并六氢吡啶衍生物及其制备方法和应用
GB201321746D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
AU2017246228B2 (en) 2016-04-04 2021-04-15 Chemocentryx, Inc. Soluble C5aR antagonists
WO2018222601A1 (en) 2017-05-31 2018-12-06 Chemocentryx, Inc. 5-5 FUSED RINGS AS C5a INHIBITORS
CN110997674B (zh) 2017-05-31 2022-12-20 凯莫森特里克斯股份有限公司 作为C5a抑制剂的6-5稠合环类
ES2980175T3 (es) 2017-12-22 2024-09-30 Chemocentryx Inc Compuestos anulares fusionados en 6,5 sustituidos con diarilo como inhibidores de C5aR
MX2020006460A (es) 2017-12-22 2020-11-06 Chemocentryx Inc Compuestos de anillo 5,5 fusionado sustituido con diarilo como inhibidores de c5ar.
WO2019195159A1 (en) 2018-04-02 2019-10-10 Chemocentryx, Inc. PRODRUGS OF FUSED-BICYCLIC C5aR ANTAGONISTS

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1777605A (zh) * 2003-04-23 2006-05-24 辉瑞产品公司 大麻素受体配位体及其用途
WO2006042102A2 (en) * 2004-10-05 2006-04-20 Neurogen Corporation Pyrrolo-pyridine, pyrrolo-pyrimidine and related heterocyclic compounds
CN104936960A (zh) * 2012-08-16 2015-09-23 詹森药业有限公司 作为n型钙通道阻滞剂的吡咯并吡唑

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Discovery and SAR of novel tetrahydropyrrolo[3,4-c]pyrazoles as inhibitors of the N-type calcium channel;Michael P.Winters，等;《Bioorganic & Medicinal Chemistry Letters》;20140501;第24卷(第9期);第2053-2056页 *

Also Published As

Publication number Publication date
WO2018222601A1 (en) 2018-12-06
MX391392B (es) 2025-03-21
MA48800A (fr) 2020-04-08
CN111032658A (zh) 2020-04-17
BR112019025230A2 (pt) 2020-06-16
JP2020522483A (ja) 2020-07-30
US10683294B2 (en) 2020-06-16
JP7141129B2 (ja) 2022-09-22
MX2019014292A (es) 2022-04-07
IL270842B2 (en) 2023-05-01
AR111841A1 (es) 2019-08-21
US20210009594A1 (en) 2021-01-14
NZ759295A (en) 2026-03-27
AU2018277523A1 (en) 2019-12-05
CA3064025A1 (en) 2018-12-06
RU2019142985A (ru) 2021-06-30
RU2019142985A3 (https=) 2021-09-03
TWI813570B (zh) 2023-09-01
KR102586710B1 (ko) 2023-10-10
AU2018277523B2 (en) 2022-06-23
EP3630774A1 (en) 2020-04-08
US20180346471A1 (en) 2018-12-06
EP3630774A4 (en) 2020-10-07
US11479553B2 (en) 2022-10-25
EP3630774B1 (en) 2022-11-23
ZA201907755B (en) 2023-05-31
ES2934507T3 (es) 2023-02-22
TW201902897A (zh) 2019-01-16
IL270842B1 (en) 2023-01-01
KR20200013720A (ko) 2020-02-07
IL270842A (en) 2020-01-30

Similar Documents

Publication Publication Date Title
CN111032658B (zh) 作为C5a抑制剂的5-5稠合环类
CN110997674B (zh) 作为C5a抑制剂的6-5稠合环类
CN111788184B (zh) 用作C5aR抑制剂的二芳基取代的5,5-稠合环化合物
ES2980175T3 (es) Compuestos anulares fusionados en 6,5 sustituidos con diarilo como inhibidores de C5aR
RU2780338C2 (ru) 6-5 КОНДЕНСИРОВАННЫЕ КОЛЬЦА КАК ИНГИБИТОРЫ С5а
RU2780322C2 (ru) 5-5 КОНДЕНСИРОВАННЫЕ КОЛЬЦА КАК ИНГИБИТОРЫ С5а
HK40026719B (en) 5-5 fused rings as c5a inhibitors
HK40026719A (en) 5-5 fused rings as c5a inhibitors
BR112019025230B1 (pt) Anéis 5-5 fundidos como inibidores de c5a, seus usos e composição farmacêutica
HK40026727A (en) 6-5 fused rings as c5a inhibitors
HK40026727B (en) 6-5 fused rings as c5a inhibitors
BR112019025049B1 (pt) Compostos com anéis 6- 5 fundidos e composição farmacêutica que os compreende
BR122024024491B1 (pt) Método in vitro para inibir a quimiotaxia celular mediada por c5a
BR122024024491A2 (pt) Compostos com anéis 6- 5 fundidos, composição farmacêutica, seus usos como inibidores de c5a e método in vitro para inibir a quimiotaxia celular mediada por c5a

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant